Chen S P, Cheung W, Heng C K, Jordan S C, Yap H K
Department of Pediatrics, National University of Singapore, Singapore.
Clin Exp Immunol. 2003 Oct;134(1):111-9. doi: 10.1046/j.1365-2249.2003.02252.x.
Interleukin-13 (IL-13) is a known modulator of monocyte function, down-regulating monocyte surface markers such as CD14 and proinflammatory cytokines. We have shown previously that lymphocyte IL-13 gene expression was up-regulated during relapses in children with steroid-responsive nephrotic syndrome (SRNS). In this study, we examined the monocyte mRNA expression and lipopolysaccharide (LPS)-stimulated intracellular production of tumour necrosis factor-alpha (TNF-alpha) and IL-8 in children with SRNS during relapse and remission. Additionally, we investigated CD14 mRNA levels, CD14 surface expression and its soluble component (sCD14) in serum. Our results showed that the percentages of TNF-alpha positive monocytes following LPS stimulation were significantly lower in nephrotic children in relapse (64.4 +/- 13.7%) compared to remission (81.6 +/- 9.0%, P < 0.005). This was associated with down-regulation of CD14 mRNA, as well as both membrane and sCD14 in patients with nephrotic relapse (82.9 +/- 10.1% and 1.23 +/- 0.30 micro g/ml, respectively) compared to remission (93.9 +/- 3.2% and 1.77 +/- 0.82 micro g/ml, respectively) (P < 0.003). Although we demonstrated a decrease in LPS-stimulated intracellular production of TNF-alpha in monocytes from patients with nephrotic relapse, we were unable to show a concomitant decrease in mRNA expression during relapses. This could be explained by down-regulation of gene expression at the translational rather than transcriptional level. In conclusion, it is conceivable that up-regulation of T-cell IL-13 production in children with active nephrotic relapse was associated with suppression of monocyte CD14 expression, down-regulating pro-inflammatory cytokine production, and could account for the increased susceptibility to bacterial sepsis seen in nephrotic children in active relapse.
白细胞介素-13(IL-13)是一种已知的单核细胞功能调节剂,可下调单核细胞表面标志物如CD14和促炎细胞因子。我们之前已经表明,在激素反应性肾病综合征(SRNS)患儿复发期间,淋巴细胞IL-13基因表达上调。在本研究中,我们检测了SRNS患儿复发期和缓解期单核细胞mRNA表达以及脂多糖(LPS)刺激后细胞内肿瘤坏死因子-α(TNF-α)和IL-8的产生。此外,我们还研究了血清中CD14 mRNA水平、CD14表面表达及其可溶性成分(sCD14)。我们的结果显示,与缓解期(81.6±9.0%)相比,复发期肾病患儿LPS刺激后TNF-α阳性单核细胞的百分比显著降低(64.4±13.7%,P<0.005)。这与肾病复发患者CD14 mRNA以及膜CD14和sCD14的下调有关,复发期分别为(82.9±10.1%和1.23±0.30μg/ml),而缓解期分别为(93.9±3.2%和1.77±0.82μg/ml)(P<0.003)。虽然我们证明了肾病复发患者单核细胞中LPS刺激后细胞内TNF-α的产生减少,但我们未能显示复发期间mRNA表达随之降低。这可以通过翻译水平而非转录水平的基因表达下调来解释。总之,可以想象,活动性肾病复发患儿T细胞IL-13产生的上调与单核细胞CD14表达的抑制、促炎细胞因子产生的下调有关,并且可以解释活动性复发的肾病患儿对细菌性败血症易感性增加的原因。